Product Description
Mechanisms of Action: ADRA2A Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Algeria | Australia | Austria | Bangladesh | Belgium | Bosnia | Bulgaria | Chile | Croatia | Cyprus | Czech | Denmark | Estonia | Finland | France | Germany | Greece | Hungary | India | Italy | Jordan | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Netherlands | Norway | Peru | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Slovakia | Slovenia | Spain | Sri Lanka | Sweden | Switzerland | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom
Approved Indications: None
Known Adverse Events: None
Company: Solvay Pharm
Company Location: 1120 BRUSSELS C9 00000
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 4: Polycystic Ovary Syndrome|Atrial Fibrillation|Hypertension|Obesity, Abdominal|Reperfusion Injury|Kidney Diseases|Diabetic Nephropathy|Obesity|Schizophrenia|Overweight|Pregnancy Outcomes|Fatty Liver|Intestinal Diseases
Phase 3: Hypertension|Other
Phase 1: Postural Orthostatic Tachycardia Syndrome
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| Chronic Pilot Study 2 | P1 |
Recruiting |
Postural Orthostatic Tachycardia Syndrome |
2025-01-01 |
|
| Acute Pilot Study 1 | P1 |
Active, not recruiting |
Postural Orthostatic Tachycardia Syndrome |
2024-12-31 |
|
| REG 15-021 | P4 |
Completed |
Reperfusion Injury |
2022-03-01 |
|
| ACTRN12617000948392 | P4 |
Not yet recruiting |
Intestinal Diseases|Fatty Liver |
2020-07-10 |